Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 10;7(2):12.
doi: 10.3390/children7020012.

New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)

Jing Chen  1 , Chana L Glasser  2
Affiliations
Review

New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)

Jing Chen et al. Children (Basel). .

Abstract

The relapse rate for children with acute myeloid leukemia (AML) remains high despite advancements in risk classification, multi-agent chemotherapy intensification, stem cell transplantation, and supportive care guidelines. Prognosis for this subgroup of children with relapsed/refractory AML remains poor. It is well known that the ceiling of chemotherapy intensification has been reached, limited by acute and chronic toxicity, necessitating alternative treatment approaches. In the last several years, our improved understanding of disease biology and critical molecular pathways in AML has yielded a variety of new drugs to target these specific pathways. This review provides a summary of antibody drug conjugates (ADCs), small molecule inhibitors, and tyrosine kinase inhibitors with an emphasis on those that are currently under clinical evaluation or soon to open in early phase trials for children with relapsed/refractory AML.

Keywords: acute myeloid leukemia; antibody drug conjugate.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic illustration of targetable pathways and drug mechanisms in pediatric acute myeloid leukemia (AML).
See this image and copyright information in PMC

References

    1. Gamis A.S., Alonzo T.A., Perentesis J.P., Meshinchi S., COG Acute Myeloid Leukemia Committee Children’s oncology group’s 2013 blueprint for research: Acute myeloid leukemia. Pediatr. Cancer. 2013;60:964–971. doi: 10.1002/pbc.24432. - DOI - PMC - PubMed
    1. Gamis A.S., Alonzo T.A., Meshinchi S., Sung L., Gerbing R.B., Raimondi S.C., Hirsch B.A., Kahwash S.B., Heerema-McKenney A., Winter L., et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase III children’s oncology group trial AAML0531. J. Clin. Oncol. 2014;32:3021–3032. doi: 10.1200/JCO.2014.55.3628. - DOI - PMC - PubMed
    1. Rasche M., Zimmermann M., Borschel L., Bourquin J.P., Dworzak M., Klingebiel T., Lehrnbecher T., Creutzig U., Klusmann J.H., Reinhardt D. Successes and challenges in the treatment of pediatric acute myeloid leukemia: A retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia. 2018;32:2167–2177. doi: 10.1038/s41375-018-0071-7. - DOI - PMC - PubMed
    1. Kuhlen M., Klusmann J.H., Hoell J.I. Molecular approaches to treating pediatric leukemias. Front. Pediatr. 2019;7:368. doi: 10.3389/fped.2019.00368. - DOI - PMC - PubMed
    1. Bolouri H., Farrar J.E., Triche T., Jr., Ries R.E., Lim E.L., Alonzo T.A., Ma Y., Moore R., Mungall A.J., Marra M.A., et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat. Med. 2018;24:103–112. doi: 10.1038/nm.4439. - DOI - PMC - PubMed

LinkOut - more resources